You are viewing the site in preview mode

Skip to main content

Advertisement

Table 5 Prediction for reimbursement cost using medical records and claims data-based comorbidity index score

From: A comparison of the Charlson comorbidity index derived from medical records and claims data from patients undergoing lung cancer surgery in Korea: a population-based investigation

   Exp[coefficient] based on medical records (95% Confidence interval) Exp[coefficient] based on claims data (95% Confidence interval)
Age[years] ≤ 49 1   1  
  50-59 1 (0.842-1.187) 1.02 (0.859-1.213)
  60-69 0.92 (0.787-1.093) 0.96 (0.813-1.131)
  ≥ 70 0.87 (0.727-1.063) 0.91 (0.751-1.106)
Gender male 1   1  
  female 0.96 (0.852-1.104) 0.97 (0.849-1.102)
Histologic subtype squamous cell carcinoma 1   1  
  adenocarcinoma 0.98 (0.872-1.110) 0.97 (0.863-1.100)
  bronchoalveolar carcinoma 0.69 (0.535-0.893) 0.69 (0.530-0.889)
  large cell carcinoma 1.05 (0.540-2.058) 1 (0.508-1.964)
  small cell carcinoma 0.38 (0.219-0.663) 0.39 (0.226-0.688)
  other 0.84 (0.521-1.362) 0.84 (0.517-1.354)
Surgical treatment type wedge resection 1   1  
  lobectomy 0.96 (0.721-1.296) 0.93 (0.697-1.253)
  pneumonectomy 1.02 (0.733-1.438) 1.01 (0.720-1.417)
  others 0.78 (0.425-1.451) 0.75 (0.402-1.386)
Pathologic stage I 1   1  
  II 1.05 (0.923-1.206) 1.04 (0.908-1.188)
  III 1.17* (1.044-1.328) 1.15* (1.020-1.295)
CCI score 0 1   1  
  1 1.11 (0.986-1.256) 0.98 (0.870-1.104)
  2+ 1.15 (0.972-1.374) 0.97 (0.859-1.094)
  1. *p < 0.05 according to multiple linear regression analysis using log-transformed reimbursement cost